GT Biopharma, a clinical-stage biotech focused on novel immuno-oncology therapies leveraging its proprietary TriKE® platform, reported a net loss of $2.8 million for Q1 2026 and increased operating expenses mainly due to SG&A costs. The company advanced key product candidates GTB-3650 and GTB-5550 with ongoing Phase 1 studies targeting hematologic malignancies and solid tumors, respectively. Despite scientific promise and unique NK cell engager technology, financial sustainability remains a concern given continued losses and limited cash runway. Future milestones include dose escalation data from ongoing trials and potential collaborations to broaden development and commercial pathways.